Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Trial Profile

A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Blepharoptosis
  • Focus Registrational; Therapeutic Use
  • Sponsors RevitaLid; RVL; RVL Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2023 According to a RVL Pharmaceuticals media release, company announced today that its prescription eye drop Upneeq, 0.1% has been selected winner in the professional treatment category as 'Best Eye Drop for Drooping Lids' in the NewBeauty 13th Annual Beauty Awards, which hits newsstand on 4 Apr, 2023. Also, previously,Upneeq was awarded the 'Best Innovation' in 2022 by this definitive authority in beauty.
    • 01 Oct 2020 According to an Osmotica Pharmaceutical media release, Charles Slonim is the lead medical monitor for this study.
    • 01 Oct 2020 Pooled analysis from two Phase 3 studies (Study RVL-1201-201 and Study RVL-1201-202) published in the Osmotica Pharmaceutical Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top